RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

VOLUNTARY ANNOUNCEMENT

Telitacicept (Brand Name: 泰爱®) Meets Primary Endpoint in Stage A of Phase III Clinical Trial for the Treatment of IgA Nephropathy in China

This announcement is made by RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司 (the "**Company**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that its global first-in-class BLyS/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in Stage A of Phase III clinical trial for the treatment of IgA Nephropathy ("**IgAN**") in China. We plan to submit a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the PRC (NMPA) for this indication.

This study is a multi-center, randomized, double-blind, placebo-controlled clinical trial that enrolled 318 adult IgAN patients who had received standard therapy. Telitacicept was administered subcutaneously at a dose of 240mg once weekly. The Stage A results showed: Compared to the control group, the Telitacicept group demonstrated a 55% reduction in the 24-hour urine protein-to-creatinine ratio (UPCR) after 39 weeks of treatment ($P<0.0001$), and demonstrated a favorable tolerability and safety profile. Detailed data will be presented at a major upcoming international medical conference.

IgAN is a common primary glomerular disease with diverse clinical manifestations, such as recurrent microscopic hematuria or gross hematuria, accompanied by varying degrees of proteinuria and some patients may develop severe hypertension or renal dysfunction. IgAN is also one of the leading causes of chronic kidney disease and end-stage renal disease ("**ESRD**") in China. Up to 40% of IgAN patients progress to ESRD within 20 years of diagnosis, creating a critical unmet medical need for novel therapeutics. The current academic view is that overproduction of galactose-deficient IgA1 ("**Gd-IgA1**") is the core and initiating factor in the pathogenesis of IgAN.

Studies have shown that B-cell lymphocyte stimulator ("**BLyS**") and a proliferation-inducing ligand ("**APRIL**") are key cytokines promoting the production of Gd-IgA1 and its antibodies. Telitacicept is a recombinant BLyS/APRIL dual-target fusion protein independently developed by the Company. It simultaneously inhibits the binding of BLyS and APRIL to their receptors on B cells, preventing abnormal B cell differentiation and maturation, and effectively reducing pathological immune responses. It is currently approved in China for the treatment of myasthenia gravis (MG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA).

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that Telitacicept (for the treatment of other indications) will ultimately be successfully marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, the People's Republic of China
August 27, 2025

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive directors.

* *For identification purpose only*